Tandem Diabetes Care Q2 Earnings: Revenue Up 8.5%, Key Metrics Highlight Growth

Tandem Diabetes Care reported Q2 revenue of $240.68 million, up 8.5% YoY, and EPS of -$0.48, compared to -$0.47 in the year-ago quarter. Key metrics show pump shipments of 30,000, sales of $85.47 million for US pumps, $70.47 million for non-US geographic sales, and $128.81 million for revenue from supplies and other.

Tandem Diabetes Care, Inc. (TNDM) released its quarterly financial results for the period ended June 30, 2025, reporting a loss of $0.48 per share, which exceeded the Zacks Consensus Estimate of a loss of $0.40 per share. This marks a 20% earnings surprise, as compared to the loss of $0.47 per share reported in the same quarter last year [1].

Revenue for the quarter totaled $240.68 million, an 8.5% year-over-year increase from $221.91 million. This figure surpassed the Zacks Consensus Estimate by 0.87% [1]. The company's U.S. pump shipments reached approximately 21,000 units, while international shipments were around 9,000 units. Revenue from U.S. pump sales amounted to $85.47 million, and non-US geographic sales totaled $70.47 million. Revenue from supplies and other items was $128.81 million [2].

The company's gross profit for the quarter was $125.9 million, representing a gross margin of 52%, up from 51% in the same period last year. However, the company reported a GAAP operating loss of $51.8 million, or 22% of sales, compared to a loss of $30.8 million, or 14% of sales, in the same quarter last year. The non-GAAP operating loss was $31.9 million, or 13% of sales, compared to $30.9 million, or 14% of sales, in the same period last year [2].

Tandem Diabetes Care also provided its 2025 financial guidance, expecting to reach $1 billion in worldwide sales for the year, with sales in the United States estimated at $700 million and sales outside the United States estimated at $300 million. The company expects a gross margin of approximately 53% to 54% for the full year [2].

Tandem Diabetes Care has shown resilience in the face of market challenges, with its stock losing about 57.9% since the beginning of the year compared to the S&P 500's gain of 7.1%. The company's earnings outlook and management commentary during the earnings call will be crucial in determining the stock's immediate price movement and future performance.

References:
[1] https://www.nasdaq.com/articles/tandem-diabetes-care-inc-tndm-reports-q2-loss-beats-revenue-estimates
[2] https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-second-quarter-2025-financial